Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Thol

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|November 1, 2018
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)Jürgen Krauter, Walter Fiedler, Richard F Schlenk, et al.
Haematologica|January 18, 2015
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupPeter Paschka, Richard F Schlenk, Verena I Gaidzik, et al.
Hemasphere|January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AMLSibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
Blood|January 13, 2012
Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMMLShinsuke Hirabayashi, Christian Flotho, Jessica Moetter, et al.
The Journal of Clinical Investigation|November 13, 2013
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsDaichi Inoue, Jiro Kitaura, Katsuhiro Togami, et al.
Annals of Hematology|June 15, 2017
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantationMichael Heuser, Razif Gabdoulline, Patrick Löffeld, et al.
Blood Advances|December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implicationNikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Blood|August 20, 2013
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AMLAnuhar Chaturvedi, Michelle Maria Araujo Cruz, Nidhi Jyotsana, et al.
Nature Communications|May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Blood Advances|April 30, 2021
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutationsMichael Heuser, Bennet Heida, Konstantin Büttner, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|November 1, 2018
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)Jürgen Krauter, Walter Fiedler, Richard F Schlenk, et al.
Haematologica|January 18, 2015
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupPeter Paschka, Richard F Schlenk, Verena I Gaidzik, et al.
Hemasphere|January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AMLSibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
Blood|January 13, 2012
Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMMLShinsuke Hirabayashi, Christian Flotho, Jessica Moetter, et al.
The Journal of Clinical Investigation|November 13, 2013
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsDaichi Inoue, Jiro Kitaura, Katsuhiro Togami, et al.
Annals of Hematology|June 15, 2017
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantationMichael Heuser, Razif Gabdoulline, Patrick Löffeld, et al.
Blood Advances|December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implicationNikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Blood|August 20, 2013
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AMLAnuhar Chaturvedi, Michelle Maria Araujo Cruz, Nidhi Jyotsana, et al.
Nature Communications|May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Blood Advances|April 30, 2021
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutationsMichael Heuser, Bennet Heida, Konstantin Büttner, et al.
Pageof 13